Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
Author | |
---|---|
Abstract | :
Ramucirumab, a recombinant human immunoglobulin G1 monoclonal antibody receptor antagonist designed to block the ligand-binding site of vascular endothelial growth factor receptor-2 (VEGFR-2), was evaluated as second-line treatment in combination with docetaxel in patients with non-small-cell lung cancer in the REVEL trial (NCT01168973). Ramucirumab significantly improved overall survival (OS) and progression-free survival (PFS). We report age subgroup analysis results primarily on the basis of a 65-year cutoff. |
Year of Publication | :
2017
|
Journal | :
Clinical lung cancer
|
Date Published | :
2017
|
ISSN Number | :
1525-7304
|
DOI | :
10.1016/j.cllc.2017.12.011
|
Short Title | :
Clin Lung Cancer
|
Download citation |